Lung cancer is the leading cause of cancer deaths among both men and women. Small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) are the two main types of lung cancer. Most lung ...

Small-cell lung cancer (SCLC), sometimes called small-cell carcinoma, causes about 10%-15% of all lung cancer. Non-small-cell lung cancer (NSCLC) causes the rest. Both include many types of ...

Non-small cell lung cancer (NSCLC) may spread at different rates. Research suggests the average time for a tumor to double in size is around 7 months. However, this is different for everyone.

Despite advances in drug development, some patients with non-small-cell lung cancer (NSCLC) have suboptimal responses to treatment. The authors of this Review provide an overview of the complexity ...

For patients with non–small-cell lung cancer (NSCLC), the outcomes for patients with resectable disease are historically poor compared with other solid organ malignancies. In recent years, there have ...

Danielle Hicks: Now I want to talk about progress in early-stage non-small cell lung cancer. There have been some developments in this space, particularly, specifically, in 2022 and 2023. Doctors Towe ...

Among patients with advanced or metastatic non-small cell lung cancer (NSCLC) with actionable genomic alterations, encouraging and durable antitumor activity was observed during treatment with ...

Practice-changing studies in advanced non–small cell lung cancer (NSCLC) presented at the 2024 American Society of Clinical Oncology Annual Meeting are discussed by Dr Ticiana Leal of Emory ...

Opdivo (nivolumab) is a brand-name IV infusion prescribed for non-small cell lung cancer (NSCLC) in some situations. This article covers topics such as side effects, dosage, and how Opdivo works.

potentially providing patients with the next generation of treatment options against insidious solid tumors beginning with non-small cell lung cancer," said President and Co-Chief Executive Maky ...